Advertisement
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Overview

Explore Alnylam Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ALNY●NASDAQ
HealthcareBiotechnology
$303.64
$11.06(3.78%)
U.S. Market opens in 16h 6m
Advertisement

Alnylam Pharmaceuticals, Inc. (ALNY)

Meyka AI Score

Z

Key Financials

Market Cap40.5B
P/E Ratio67.18
EPS (TTM)$3.99
ROE0.98%
Fundamental Analysis

AI Price Forecasts

1 Month$361.79
3 Months$429.08
1 Year Target$361.64

ALNY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alnylam Pharmaceuticals, Inc. (ALNY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 45.38, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $361.64.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 67.18 and a market capitalization of 40.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
3.78%
5-Day Change
0.40%
1-Month Change
1.92%
3-Month Change
-7.23%
6-Month Change
-34.75%
Year-to-Date (YTD) Change
-23.64%
1-Year Change
-0.55%
3-Year Change
57.90%
5-Year Change
108.54%
All-Time (Max) Change
4952.25%

Contact Information

https://www.alnylam.com
617 551 8200
675 West Kendall Street, Cambridge, MA, 02142

Company Facts

2,230 Employees
IPO DateJun 1, 2004
CountryUS
Actively Trading

Frequently Asked Questions